Vitamin D: The Unsung Hero in Cancer Prevention and Longevity for Metabolic Syndrome Patients
In the realm of health and wellness, Vitamin D has emerged as a significant player in the prevention of certain types of cancers and in promoting longevity, particularly among individuals with Metabolic Syndrome (MetS). MetS is a cluster of conditions that occur together, increasing your risk of heart disease, stroke, and type 2 diabetes. This study delves into the relationship between Vitamin D levels, specifically 25-hydroxyvitamin D [25(OH)D], and the incidence of 16 different types of cancer, as well as overall mortality rates in patients with MetS.
The study involved a cohort of 97,621 participants from the UK Biobank, all diagnosed with MetS. The researchers found that higher levels of 25(OH)D were inversely related to the risk of colon, lung, and kidney cancer. In simpler terms, the higher the Vitamin D levels, the lower the risk of these cancers. However, the study found no significant correlation between Vitamin D levels and the incidence of several other types of cancer, including stomach, liver, and breast cancer, among others.
The study also observed an "L-shaped" nonlinear dose-response correlation between 25(OH)D and cancer/all-cause mortality, suggesting that maintaining sufficient Vitamin D levels could potentially reduce the risk of death from cancer and other causes. These findings underscore the importance of Vitamin D in cancer prevention and longevity promotion among patients with MetS.
Article Information
Association of serum 25-hydroxyvitamin D with the incidence of 16 cancers, cancer mortality, and all-cause mortality among individuals with metabolic syndrome: a prospective cohort study
Published on Eur J Nutr by E Wu et al.
Abstract
Purpose: The relationship between vitamin D levels and cancer incidence and mortality in individuals with metabolic syndrome (MetS) remains poorly explored. Herein, we aimed to determine the association between 25-hydroxyvitamin D [25(OH)D] concentrations and the risk of 16 cancer incidence types and cancer/all-cause mortality in patients with MetS.
Methods: We enrolled 97,621 participants with MetS at recruitment from the UK Biobank cohort. The exposure factor was baseline serum 25(OH)D concentrations. The associations were examined using Cox proportional hazards models, which were displayed as hazard ratios (HRs) with 95% confidence intervals (CIs).
Results: Over a median follow-up period of 10.92 years for cancer incidence outcomes, 12,137 new cancer cases were recorded. We observed that 25(OH)D concentrations were inversely related to the risk of colon, lung, and kidney cancer, and HRs (95% CI) for 25(OH)D ≥ 75.0 vs. < 25.0 nmol/L were 0.67 (0.45-0.98), 0.64 (0.45-0.91), and 0.54 (0.31-0.95), respectively. The fully adjusted model revealed a null correlation between 25(OH)D and the incidence of stomach, rectum, liver, pancreas, breast, ovary, bladder, brain, multiple myeloma, leukemia, non-Hodgkin lymphoma, esophagus, and corpus uteri cancer. Over a median follow-up period of 12.72 years for mortality outcomes, 8286 fatalities (including 3210 cancer mortalities) were documented. An "L-shaped" nonlinear dose-response correlation was detected between 25(OH)D and cancer/all-cause mortality; the respective HRs (95% CI) were 0.75 (0.64-0.89) and 0.65 (0.58-0.72).
Conclusion: These findings emphasize the importance of 25(OH)D in cancer prevention and longevity promotion among patients with MetS.
Bring preventive care to your clinic
© Longevity Artificial Intelligence. All rights reserved.